[go: up one dir, main page]

MX2022006495A - Tratamiento para la sobrecarga fisiologica de hierro. - Google Patents

Tratamiento para la sobrecarga fisiologica de hierro.

Info

Publication number
MX2022006495A
MX2022006495A MX2022006495A MX2022006495A MX2022006495A MX 2022006495 A MX2022006495 A MX 2022006495A MX 2022006495 A MX2022006495 A MX 2022006495A MX 2022006495 A MX2022006495 A MX 2022006495A MX 2022006495 A MX2022006495 A MX 2022006495A
Authority
MX
Mexico
Prior art keywords
iron
treatment
iron overload
mtpâ
mtp
Prior art date
Application number
MX2022006495A
Other languages
English (en)
Inventor
Matthew Wake
Volker Germaschewski
Igor Theurl
Jonathan Leslie Papworth
Delphine Meynard
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1917524.9A external-priority patent/GB201917524D0/en
Priority claimed from GBGB1917882.1A external-priority patent/GB201917882D0/en
Application filed by Kymab Ltd filed Critical Kymab Ltd
Publication of MX2022006495A publication Critical patent/MX2022006495A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hydrogen, Water And Hydrids (AREA)
  • Treatment Of Water By Oxidation Or Reduction (AREA)
  • Reciprocating, Oscillating Or Vibrating Motors (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se presentan anticuerpos contra la enzima matriptasa-2 (MTP-2). La inhibición de la MTP-2 reduce la absorción de hierro dietético y reduce la liberación de hierro de las reservas celulares en el cuerpo. Los inhibidores de la MTP-2 (como los anticuerpos contra el dominio de la proteasa de serina) se pueden usar para tratar la sobrecarga de hierro, que es una característica de enfermedades como la beta-talasemia y que de otro modo conduce a la acumulación tóxica de hierro. La combinación de un inhibidor de la MTP-2 con una trampa de ligando de receptor de activina o con eritropoyetina proporciona los efectos terapéuticos adicionales.
MX2022006495A 2019-11-29 2020-11-27 Tratamiento para la sobrecarga fisiologica de hierro. MX2022006495A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1917524.9A GB201917524D0 (en) 2019-11-29 2019-11-29 Treatment for physiological iron overload
GBGB1917882.1A GB201917882D0 (en) 2019-12-06 2019-12-06 Treatment for physiological iron overload
PCT/EP2020/083677 WO2021105389A1 (en) 2019-11-29 2020-11-27 Treatment for physiological iron overload

Publications (1)

Publication Number Publication Date
MX2022006495A true MX2022006495A (es) 2022-09-07

Family

ID=73698783

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006495A MX2022006495A (es) 2019-11-29 2020-11-27 Tratamiento para la sobrecarga fisiologica de hierro.

Country Status (12)

Country Link
US (1) US20230025129A1 (es)
EP (1) EP4065607A1 (es)
JP (2) JP7709436B2 (es)
KR (1) KR20220107252A (es)
CN (1) CN115380049A (es)
BR (1) BR112022010424A2 (es)
CA (1) CA3162880A1 (es)
CO (1) CO2022009078A2 (es)
IL (1) IL293314A (es)
MX (1) MX2022006495A (es)
PH (1) PH12022551299A1 (es)
WO (1) WO2021105389A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3174339A1 (en) 2020-04-07 2021-10-14 Xin Du Anti-tmprss6 antibodies and uses thereof
BR112023023558A2 (pt) 2021-05-11 2024-03-12 Regeneron Pharma Anticorpos anti-tmprss6 e usos dos mesmos
CN113667600B (zh) * 2021-07-21 2023-08-11 青岛海特生物医疗有限公司 用于二氧化碳培养箱功率分配的方法、装置及二氧化碳培养箱

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US20050054027A1 (en) 2003-09-09 2005-03-10 Irm Llc Modulators of transmembrane protease serine 6
GB0614201D0 (en) 2006-07-18 2006-08-23 Univ Cardiff Matriptase-2
ES2396734T3 (es) 2006-12-18 2013-02-25 Acceleron Pharma, Inc. Antagonistas de ACTIVINA-ACTRII y sus usos para tratar la anemia
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
NZ597481A (en) 2009-07-08 2013-10-25 Kymab Ltd Animal models and therapeutic molecules
SG186238A1 (en) 2010-06-17 2013-01-30 Kymab Ltd Animal models and therapeutic molecules
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
WO2016071701A1 (en) * 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
WO2016085852A1 (en) * 2014-11-24 2016-06-02 Alnylam Pharmaceuticals, Inc. Tmprss6 irna compositions and methods of use thereof
NZ739392A (en) 2015-07-31 2019-10-25 Medimmune Ltd Methods for treating hepcidin-mediated disorders
CN105219780B (zh) * 2015-10-30 2020-06-02 中国人民解放军第三军医大学第一附属医院 抗多亚基因型hcv抗体基因r3-19及其应用

Also Published As

Publication number Publication date
WO2021105389A1 (en) 2021-06-03
US20230025129A1 (en) 2023-01-26
CA3162880A1 (en) 2021-06-03
BR112022010424A2 (pt) 2022-08-23
CO2022009078A2 (es) 2022-09-20
EP4065607A1 (en) 2022-10-05
CN115380049A (zh) 2022-11-22
KR20220107252A (ko) 2022-08-02
IL293314A (en) 2022-07-01
JP7709436B2 (ja) 2025-07-16
JP2025166832A (ja) 2025-11-06
JP2023503513A (ja) 2023-01-30
PH12022551299A1 (en) 2023-11-20

Similar Documents

Publication Publication Date Title
PH12021552497A1 (en) Enzyme inhibitors
MX2020008777A (es) Inmunoterapias relacionadas con el microbioma.
PH12022551299A1 (en) Treatment for physiological iron overload
ZA201906269B (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
IL184678A0 (en) Proteasome inhibitors and methods of using the same
IL182218A0 (en) Preparation and use of biphenyl-4-yl-carbonylamino and derivatives for the treatment of obesity
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
TW200605886A (en) Indazoles useful in treating cardiovascular diseases
PH12012501372B1 (en) Proteasome inhibitors and methods of using the same
PH12014500832A1 (en) Methods for treating hcv
MX2011006685A (es) Inhibidores de metaloproteinas de matriz de membrana tipo-1 y sus usos.
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
EA202090944A1 (ru) Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
PH12022551052A1 (en) Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).
MY148647A (en) Pharmaceutical compositions comprising a camtothecin derivative
NO20065297L (no) Anvendelse av GPCR54 ligander til behandling av infertilitet
ZA201901367B (en) Inhibition of olig2 activity
WO2019115493A3 (en) C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
DE602006012313D1 (de) Kombination aus pyrimidylaminobenzamid-verbindungen und imatinib zur behandlung oder verhinderung proliferativer erkrankungen
PH12021550134A1 (en) Therapeutic or prophylactic agent for htlv-1-associated myelopathy (ham), and method for treating ham
UA96736C2 (ru) Ингибиторы pi3k для лечения эндометриоза